JP6240500B2 - スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 - Google Patents

スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 Download PDF

Info

Publication number
JP6240500B2
JP6240500B2 JP2013508229A JP2013508229A JP6240500B2 JP 6240500 B2 JP6240500 B2 JP 6240500B2 JP 2013508229 A JP2013508229 A JP 2013508229A JP 2013508229 A JP2013508229 A JP 2013508229A JP 6240500 B2 JP6240500 B2 JP 6240500B2
Authority
JP
Japan
Prior art keywords
aars
protein
polypeptide
item
tables
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013508229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531973A (ja
JP2013531973A5 (2
Inventor
レスリー アン グリーン，
レスリー アン グリーン，
カイル ピー． チャン，
カイル ピー． チャン，
フェイ ホン，
フェイ ホン，
アレイン ピー． バサロット，
アレイン ピー． バサロット，
ウィン−セー ロー，
ウィン−セー ロー，
ジェフリー ディー． ワトキンス，
ジェフリー ディー． ワトキンス，
ジョン ディー． メンドレイン，
ジョン ディー． メンドレイン，
シェリル エル． クイン，
シェリル エル． クイン，
Original Assignee
エータイアー ファーマ， インコーポレイテッド
エータイアー ファーマ， インコーポレイテッド
パング バイオファーマ リミテッド
パング バイオファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エータイアー ファーマ， インコーポレイテッド, エータイアー ファーマ， インコーポレイテッド, パング バイオファーマ リミテッド, パング バイオファーマ リミテッド filed Critical エータイアー ファーマ， インコーポレイテッド
Publication of JP2013531973A publication Critical patent/JP2013531973A/ja
Publication of JP2013531973A5 publication Critical patent/JP2013531973A5/ja
Application granted granted Critical
Publication of JP6240500B2 publication Critical patent/JP6240500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • C12Y601/01003—Threonine-tRNA ligase (6.1.1.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
JP2013508229A 2010-04-27 2011-04-27 スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 Active JP6240500B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32837310P 2010-04-27 2010-04-27
US32837110P 2010-04-27 2010-04-27
US32836910P 2010-04-27 2010-04-27
US61/328,369 2010-04-27
US61/328,371 2010-04-27
US61/328,373 2010-04-27
PCT/US2011/034207 WO2011139801A2 (en) 2010-04-27 2011-04-27 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015142866A Division JP2015186486A (ja) 2010-04-27 2015-07-17 スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP2017163371A Division JP2017201994A (ja) 2010-04-27 2017-08-28 スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見

Publications (3)

Publication Number Publication Date
JP2013531973A JP2013531973A (ja) 2013-08-15
JP2013531973A5 JP2013531973A5 (2) 2014-05-22
JP6240500B2 true JP6240500B2 (ja) 2017-11-29

Family

ID=44904372

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013508229A Active JP6240500B2 (ja) 2010-04-27 2011-04-27 スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP2015142866A Pending JP2015186486A (ja) 2010-04-27 2015-07-17 スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP2017163371A Withdrawn JP2017201994A (ja) 2010-04-27 2017-08-28 スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015142866A Pending JP2015186486A (ja) 2010-04-27 2015-07-17 スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP2017163371A Withdrawn JP2017201994A (ja) 2010-04-27 2017-08-28 スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見

Country Status (8)

Country Link
US (4) US8986681B2 (2)
EP (1) EP2563382B1 (2)
JP (3) JP6240500B2 (2)
CN (2) CN103096910A (2)
AU (1) AU2011248521B2 (2)
CA (1) CA2797259C (2)
ES (1) ES2638311T3 (2)
WO (1) WO2011139801A2 (2)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099477A2 (en) 2009-02-27 2010-09-02 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
EP2563382B1 (en) 2010-04-27 2017-06-07 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CN103096912A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
CA2797799C (en) 2010-05-03 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US9062301B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103096914B (zh) 2010-05-17 2015-08-12 Atyr医药公司 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
EP2575857B1 (en) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
US20130202576A1 (en) 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
WO2012009289A2 (en) 2010-07-12 2012-01-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
CA2812795C (en) 2010-10-06 2021-08-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases
WO2012158945A2 (en) * 2011-05-19 2012-11-22 The Scripps Research Institute Compositions and methods for treating charcot-marie-tooth diseases and related neuronal diseases
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
WO2013115926A2 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
US10175237B2 (en) 2012-07-25 2019-01-08 University Of Vermont And State Agricultural College Methods and compounds for diagnosing threonyl-tRNA synthetase-associated diseases and conditions
WO2014018619A1 (en) * 2012-07-25 2014-01-30 University Of Vermont And State Agricultural College Methods and compounds for increasing threonyl-trna synthetase activity
WO2014018620A1 (en) * 2012-07-25 2014-01-30 University Of Vermont And State Agricultural College Methods and compounds for reducing threonyl-trna synthetase activity
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
WO2019055594A1 (en) 2017-09-13 2019-03-21 North Carolina State University BRUSHING ADIPOSE TISSUE INDUCED LOCALLY BY MICRO-NEEDLE STAMPS FOR THE TREATMENT OF OBESITY
CN110317867A (zh) * 2019-07-11 2019-10-11 德阳市人民医院 Tars作为诊断男性骨质疏松症的分子标志物的应用
CN110567861B (zh) * 2019-09-09 2021-12-21 浙江普罗亭健康科技有限公司 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法
CN115666627A (zh) * 2020-03-25 2023-01-31 韩国生命工学研究院 源自嗜黏蛋白阿克曼菌的tars或其片段，及其用途
CN112067515B (zh) * 2020-09-03 2023-04-25 南昌大学 一种均相检测大分子抗原的动态光散射免疫方法

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9115660U1 (de) 1991-12-18 1992-07-30 Aventis Research & Technologies GmbH & Co KG, 65929 Frankfurt L-Phenylalanyl-tRNA-Synthetase mit erweiterter Substratselektivität aus Mikroorganismen
US5759833A (en) 1994-05-27 1998-06-02 Cubist Pharmaceuticals, Inc. Human isoleucyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same
US5798240A (en) 1994-09-13 1998-08-25 Cubist Pharmaceuticals, Inc. Recombinant mycobacterial methionyl-tRNA synthetase genes and methods of use therefore
US5756327A (en) 1994-09-13 1998-05-26 Cubist Pharmaceuticals, Inc. Recombinant mycobacterial isoleucyl-tRNA synthetase genes, tester strains and assays
US5801013A (en) 1995-05-26 1998-09-01 Cubist Pharmaceuticals, Inc. Helicobacter aminoacyl-tRNA synthetase proteins, nucleic acids and strains comprising same
BR9707125A (pt) 1996-01-11 1999-07-20 Corixa Corp Composições e processos para o tratamento e diagnóstico de câncer de mama
WO1997026342A1 (en) 1996-01-19 1997-07-24 Smithkline Beecham Plc THREONYL-tRNA SYNTHETASE OF STAPHYLOCOCCUS AUREUS
US5795757A (en) 1997-01-17 1998-08-18 Smithkline Beecham, P.L.C. DNA encoding threonyl tRNA synthetase from staphylococcus aureus
US5756329A (en) 1996-01-19 1998-05-26 Smithkline Beecham P.L.C. DNA encoding phenylalanyl tRNA synthetase from Staphylococcus aureus
GB9601067D0 (en) 1996-01-19 1996-03-20 Smithkline Beecham Plc Novel compounds
GB9607991D0 (en) 1996-04-18 1996-06-19 Smithkline Beecham Plc Novel compounds
GB9607993D0 (en) * 1996-04-18 1996-06-19 Smithkline Beecham Plc Novel compounds
US5795758A (en) 1997-04-18 1998-08-18 Smithkline Beecham Corporation DNA encoding histidyl tRNA synthetase variant from Streptococcus pneumoniae
KR100203919B1 (ko) 1996-10-04 1999-06-15 신동권 수용성 단백질을 생산하는 새로운 발현 플라스미드
US5885815A (en) 1996-11-01 1999-03-23 Cubist Pharmaceuticals, Inc. Candida isoleucyl-tRNA synthetase proteins, nucleic acids and strains comprising same
US5776749A (en) 1997-01-17 1998-07-07 Smithkline Beecham P.L.C. DNA encoding cysteinyl tRNA synthetase from Staphylococcus aureus
CA2289116A1 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
US5939298A (en) 1997-07-23 1999-08-17 Smithkline Beecham Corporation DNA encoding phenylalanyl tRNA synthetase alpha sub-unit from chlamydi a trachomatis
US5858720A (en) 1997-07-23 1999-01-12 Smithkline Beecham Corporation Hiss
US5882892A (en) 1997-07-23 1999-03-16 Smithkline Beecham Corporation Asps
CA2321261A1 (en) 1998-03-04 1999-09-10 Onyx Pharmaceuticals, Inc. Baculovirus expression system and method for high throughput expression of genetic material
US6428960B1 (en) 1998-03-04 2002-08-06 Onyx Pharmaceuticals, Inc. Selection method for producing recombinant baculovirus
US6255090B1 (en) 1998-07-15 2001-07-03 E. I. Du Pont De Nemours & Company Plant aminoacyl-tRNA synthetase
US6271441B1 (en) 1998-07-21 2001-08-07 E. I. Du Pont De Nemours & Company Plant aminoacyl-tRNA synthetase
US6696619B1 (en) * 1998-11-05 2004-02-24 Omolayo O. Famodu Plant aminoacyl-tRNA synthetases
AU6364700A (en) 1999-07-22 2001-02-13 Incyte Genomics, Inc. Human synthetases
WO2001019999A1 (en) * 1999-09-14 2001-03-22 Shanghai Biorigin Gene Development Co. Ltd. A GENE ENCODING A NOVEL THREONYL-tRNA SYNTHETASE, ITS USES AND THE PREPARING METHODS
CN1375007A (zh) * 1999-09-14 2002-10-16 上海生元基因开发有限公司 编码一种新的苏氨酰转移核糖核酸合成酶的基因及其应用和制备方法
US6548060B1 (en) 1999-11-18 2003-04-15 Sunghoon Kim Anti-apoptotic use of human glutaminyl-tRNA synthetase with two consecutive pro-apoptotic mediators
CN1311300A (zh) * 2000-03-02 2001-09-05 上海博德基因开发有限公司 一种新的多肽－人苏氨酰－tRNA合成酶14和编码这种多肽的多核苷酸
US7144984B2 (en) 2000-03-31 2006-12-05 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001245899B2 (en) 2000-03-31 2006-06-15 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US7273844B2 (en) 2000-03-31 2007-09-25 The Scripps Research Institute Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN1322818A (zh) 2000-05-09 2001-11-21 上海博德基因开发有限公司 一种新的多肽——人II类氨酰基－tRNA合成酶10和编码这种多肽的多核苷酸
WO2001088188A2 (en) 2000-05-18 2001-11-22 Nihon University, School Juridical Person Method for examining ischemic conditions
JP2004510407A (ja) 2000-05-25 2004-04-08 インサイト・ゲノミックス・インコーポレイテッド アミノアシルｔＲＮＡ合成酵素
CN1341725A (zh) * 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——人苏氨酰－tRNA合成酶48.73和编码这种多肽的多核苷酸
CN1341727A (zh) 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——甲硫氨酰tRNA合成酶35.09和编码这种多肽的多核苷酸
CN1352242A (zh) 2000-11-02 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人谷氨酰tRNA合成酶12.65和编码这种多肽的多核苷酸
CN1352252A (zh) 2000-11-06 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人II类氨酰基－tRNA合成酶11.77和编码这种多肽的多核苷酸
WO2002044349A2 (en) 2000-11-28 2002-06-06 Mcgill University INCORPORATION AND PRIMING FUNCTION OF tRNALYS IN HIV AND RELATED VIRUSES
EP1349939A2 (en) 2000-12-15 2003-10-08 Incyte Genomics, Inc. Aminoacyl trna synthetases
ES2318063T3 (es) 2001-02-23 2009-05-01 The Scripps Research Institute Polipeptidos derivados de la triptofanil arnt sintetasa utiles para la regulacion de la angiogenesis.
US6903189B2 (en) 2001-03-21 2005-06-07 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
US20030215827A1 (en) 2001-05-22 2003-11-20 Henry Yue Aminoacyl trna synthetases
KR100405919B1 (ko) 2001-06-05 2003-11-14 주식회사 이매진 ｐ43의 Ｎ-말단 펩타이드를 유효성분으로 하는 면역증강용 약학조성물
US20040018505A1 (en) 2001-06-29 2004-01-29 Lee Ernestine A. Aminoacyl trna synthetases
AU2002332430A1 (en) 2001-07-26 2003-02-17 Novartis Ag Methods of treating neuropilin-mediated diseases
US7785827B2 (en) 2001-09-20 2010-08-31 University Of Houston System Method and composition for leucyl-tRNA synthetases and derivatives thereof that activate and aminoacylate non-leucine amino acid to tRNA adaptor molecules
US20040048290A1 (en) 2001-12-13 2004-03-11 Lee Ernestine A Aminoacyl trna synthetases
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6940080B2 (en) 2002-03-28 2005-09-06 Kabushiki Kaisha Toshiba Charged particle beam lithography system, lithography method using charged particle beam, method of controlling charged particle beam, and method of manufacturing semiconductor device
WO2003094862A2 (en) 2002-05-13 2003-11-20 Rigel Pharmaceuticals, Inc. tRNA SYNTHASE: MODULATORS OF ANGIOGENESIS
US20060248617A1 (en) 2002-08-30 2006-11-02 Japan Science And Technology Corporation Method of targeted gene disruption, genome of hyperthermostable bacterium and genome chip using the same
JP4664677B2 (ja) 2002-09-06 2011-04-06 イソゲニカ リミテッド イン・ビトロでのペプチド発現ライブラリー
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004060262A2 (en) 2003-01-07 2004-07-22 Lorantis Limited Modulators of notch signalling for use in immunotherpapy
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
WO2004087875A2 (en) 2003-03-25 2004-10-14 Incyte Corporation Nucleic acid-associated proteins
JP2007502861A (ja) 2003-05-01 2007-02-15 レプリダイン・インコーポレーテッド 抗菌方法及び組成物
WO2005019415A2 (en) 2003-07-07 2005-03-03 The Scripps Research Institute Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
AU2004321117B2 (en) 2003-12-18 2010-09-02 The Scripps Research Institute Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
KR100599454B1 (ko) 2004-04-27 2006-07-12 재단법인서울대학교산학협력재단 종양 억제자로 작용하는 ａｉｍ3의 신규 용도
ATE551060T1 (de) 2004-06-04 2012-04-15 Scripps Research Inst Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
US20060078553A1 (en) 2004-10-07 2006-04-13 Paul Glidden Diverse multi-unit complexes including a tRNA synthetase fragment
US20060079673A1 (en) 2004-08-02 2006-04-13 Paul Glidden Polynucleotides encoding tRNA synthetase fragments and uses thereof
US20060024288A1 (en) 2004-08-02 2006-02-02 Pfizer Inc. tRNA synthetase fragments
US8282921B2 (en) 2004-08-02 2012-10-09 Paul Glidden tRNA synthetase fragments
US7459529B2 (en) 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
US8003780B2 (en) 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
CN102732588B (zh) 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
MX2008002149A (es) 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
US8026088B2 (en) 2005-12-02 2011-09-27 The Scripps Research Institute Angiogenic tyrosyl tRNA synthetase compositions and methods
AU2007224019A1 (en) 2006-03-03 2007-09-13 California Institute Of Technology Site-specific incorporation of amino acids into molecules
NZ573407A (en) 2006-05-26 2012-09-28 Obodies Ltd Ob fold domains
US20100120627A1 (en) 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
EP2520935A3 (en) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2064316B1 (en) 2006-09-08 2012-01-25 Ambrx, Inc. Site specific incorporation of non-natural amino acids by vertebrate cells
ATE502960T1 (de) 2006-11-17 2011-04-15 Novartis Ag Lingo bindende moleküle und pharmazeutische verwendung davon
US20100138941A1 (en) 2007-04-27 2010-06-03 Imagene Co., Ltd. Method for screening immune modulator
JP2009017840A (ja) * 2007-07-13 2009-01-29 Japan Agengy For Marine-Earth Science & Technology 外来遺伝子を細胞に安定に保持する方法
WO2009059056A2 (en) 2007-11-02 2009-05-07 The Scripps Research Institute A genetically encoded boronate amino acid
JP5585904B2 (ja) 2008-02-08 2014-09-10 独立行政法人理化学研究所 アミノアシルｔＲＮＡ合成酵素活性を有するポリペプチド及びその利用
MX2010010068A (es) 2008-03-11 2010-10-04 Univ North Carolina Composiciones angiostaticas que comprenden polipeptidos de tirosil-acido ribonucleico de transferencia sintetasa truncado y metodos de uso de las mismas.
CN102105164A (zh) 2008-06-11 2011-06-22 Atyr医药公司 酪氨酰-trna合成酶多肽的血小板生成活性
US8404471B2 (en) 2008-06-26 2013-03-26 Atyr Pharma, Inc. Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities
CA2734892A1 (en) 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
KR101067817B1 (ko) 2008-10-10 2011-09-27 서울대학교산학협력단 Ａｉｍｐ1 폴리펩티드에 대한 항체를 포함하는 관절염 진단용 조성물
WO2010041913A2 (ko) 2008-10-10 2010-04-15 서울대학교산학협력단 Grs 단백질 또는 이의 단편의 신규한 용도
KR101067815B1 (ko) 2009-02-05 2011-09-27 서울대학교산학협력단 제1형 당뇨병의 신규한 진단 마커
WO2010096170A2 (en) * 2009-02-19 2010-08-26 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
WO2010099477A2 (en) * 2009-02-27 2010-09-02 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
EP2408905B1 (en) 2009-03-16 2017-05-10 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
CN102449143B (zh) 2009-03-31 2017-11-14 Atyr医药公司 包含具有非常规生物活性的天冬氨酰‑tRNA合成酶的组合物和方法
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
CN106474462A (zh) * 2009-12-11 2017-03-08 Atyr 医药公司 用于调节炎症的氨酰tRNA合成酶
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
US8828685B2 (en) 2010-02-04 2014-09-09 The Scripps Research Institute Monomeric forms of human aminoacyl-t-RNA synthetases having non-canonical biological activities
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
EP2563382B1 (en) 2010-04-27 2017-06-07 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CA2797799C (en) 2010-05-03 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
CN103096912A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9062301B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103096914B (zh) 2010-05-17 2015-08-12 Atyr医药公司 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
EP2575857B1 (en) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US20130202576A1 (en) 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
WO2012009289A2 (en) 2010-07-12 2012-01-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
CA2812795C (en) 2010-10-06 2021-08-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases
WO2012158945A2 (en) 2011-05-19 2012-11-22 The Scripps Research Institute Compositions and methods for treating charcot-marie-tooth diseases and related neuronal diseases
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
WO2013115926A2 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
MX356107B (es) 2012-02-16 2018-05-15 Atyr Pharma Inc Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
US20140066321A1 (en) 2012-07-23 2014-03-06 Pangu Biopharma Limited Structures of human histidyl-trna synthetase and methods of use
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物

Also Published As

Publication number Publication date
CN108165537A (zh) 2018-06-15
EP2563382A4 (en) 2013-11-20
US20150284706A1 (en) 2015-10-08
JP2015186486A (ja) 2015-10-29
JP2013531973A (ja) 2013-08-15
WO2011139801A3 (en) 2012-03-29
US8986681B2 (en) 2015-03-24
US20190218542A1 (en) 2019-07-18
JP2017201994A (ja) 2017-11-16
US20130129704A1 (en) 2013-05-23
ES2638311T3 (es) 2017-10-19
US10563192B2 (en) 2020-02-18
EP2563382A2 (en) 2013-03-06
EP2563382B1 (en) 2017-06-07
US20170246296A1 (en) 2017-08-31
WO2011139801A2 (en) 2011-11-10
US9580706B2 (en) 2017-02-28
AU2011248521B2 (en) 2017-03-16
US10150958B2 (en) 2018-12-11
CA2797259C (en) 2020-09-29
AU2011248521A1 (en) 2012-12-06
CA2797259A1 (en) 2011-11-10
CN103096910A (zh) 2013-05-08

Similar Documents

Publication Publication Date Title
JP6240500B2 (ja) スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6360594B2 (ja) セリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6473178B2 (ja) グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6008841B2 (ja) メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP5976638B2 (ja) アルギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6027965B2 (ja) ロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6294074B2 (ja) イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6066900B2 (ja) システイニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP5906237B2 (ja) リジルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6177129B2 (ja) ヒスチジルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6039566B2 (ja) 治療用、診断用および抗体組成物に関連したトリプトファニルｔＲＮＡ合成酵素のタンパク質フラグメントの革新的発見
JP5991963B2 (ja) バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6396656B2 (ja) フェニルアラニルβｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6008843B2 (ja) グルタミル−プロリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP2013530938A (ja) ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP2013534413A (ja) グルタミニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160415

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160602

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171106

R150 Certificate of patent or registration of utility model

Ref document number: 6240500

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250